P-0280 - The Adjuvant treatment of rectal cáncer in elderly

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Anti-Cancer Agents & Biologic Therapy
Geriatric Oncology
Rectal Cancer
Surgery and/or Radiotherapy of Cancer
Presenter Julia Ruiz-Vozmediano
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors R. Luque-Caro
  • Hospital Universitario Virgen de las Nieves, Granada/ES



The adjuvant treatment of rectal cáncer (RC) after the use of preoperative treatment with chemotherapy-radiotherapy (QT-RT) is not totally established in general population. The RC patients older than 70 years old present more co-morbidity and they are more susceptible to present associated side effects with the treatment. This retrospective study analyzes this subgroup of patients, values the toxicity and the efficacy about the patients younger than 70 years old.


108 patients were included in this study of which 45 were older than 70 old (16 women and 29 men). All the patients received preoperative treatment with QT-RT, in 18 patients abdominoperitoneal amputation and 27 previous below resection was realised. 24 patients present partial pathological response, 3 patients completely pathological response, 7 patients tumoral stabilization and 11 patients tumoral progression.


The adjuvant treatment administrated was capecitabine in 18 patients (42,22%), capecitabine + oxaliplatin in 10 patients (22,22%), and 16 patients (35,55%) did not receive the adjuvant treatment. There were not any deaths due to adjuvant treatment and the main toxicity grade 3-4 was hand-food syndrome in 3 patients (10,33%) and haematological toxicity (neutropenia) in 1 patient (3,44%). After a follow- up median of 33 months, the overall survival (OS) in patients older than 70 years was 51 months and there was not statistically significant differences (p= 0,73) with patients younger than 70 years (OS = 51,50 months). The progression free survival (PFS) was 29,50 months without differences with younger than 70 years old(PFS = 28 months, p= 0,92).


In our experience, the patients older than 70 years old with RC should be treated with the same treatment as the general population. Considering the co-morbidities in each patient for the choice of treatment. It would be desirable the design of specific clinical trials in this patients population.